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Abstract
Outcomes studies of infections with resistant bacteria often do not
account appropriately for intermediate variables – events in the
causal pathway between the exposure and the outcome – when
controlling for confounders. We discuss how failure to distinguish
between confounders and intermediate variables can bias the
analysis, and we address methods of approaching this issue.
Antimicrobial resistance in invasive infections is associated
with adverse outcomes, including increased mortality,
increased length of stay, and increased hospital costs [1-4].
A number of reasons have been suggested for this
observation: a delay in institution of effective therapy, inferior
definitive therapy as compared with that available for
susceptible bacteria, and greater virulence of some resistant
strains [3-5]. Pseudomonas aeruginosa, although inherently
resistant to numerous antibiotics, appears to be no exception
to this phenomenon: a number of studies have demonstrated
an association between still broader resistance and mortality
in infections caused by this pathogen [6,7].
In the previous issue of Critical Care, Zavascki and
colleagues report the results of a prospective cohort study of
mortality associated with hospital-acquired pneumonia
caused by P. aeruginosa [8]. The authors looked specifically
at the effect on outcome of the production of metallo-β-
lactamase (MBL), a group of carbapenamases that hydrolyze
all  β-lactam antibiotics with the exception of aztreonam. In
crude analysis of 150 patients, MBL production was
significantly associated with increased 30-day mortality, with
a nearly twofold relative risk. In multivariable analysis, MBL
production remained a significant predictor of mortality until
inclusion of the variable ‘appropriate antimicrobial therapy’,
which caused MBL production to lose its significance. The
authors postulate that the collinearity between these two
covariates demonstrates that MBL production leads to the
administration of inappropriate therapy, which in turn
increases mortality.
Another way to describe this phenomenon is that
appropriateness of therapy is an intermediate variable; that is,
a variable in the causative pathway between infection with a
resistant organism (the exposure) and mortality (the
outcome). Accordingly, infection with an MBL producer leads
to inappropriate therapy, which in turn leads to increased
mortality. This scenario is a prime example of how adjustment
for intermediate variables may bias the association between
exposure and outcome, often reducing its magnitude and
even depriving it of statistical significance. In the case of
inappropriate therapy and resistance, Zavascki and
colleagues have correctly presented both models (with and
without the variable appropriateness of therapy), and
plausibly concluded that MBL production leads to increased
mortality by causing a delay in appropriate therapy [8].
Zavascki and colleagues, however, do not account for
adjustment for the variables ‘severe sepsis/septic shock’ and
‘bacteremia’ in the same manner. These are also intermediate
variables, in the causative pathway between the exposure and
the outcome. The methodologic flaw of adjusting for
intermediate variables without accounting for them as such is
common to many outcome studies of infections in seriously ill
patients [9-11], and may bias the results [12,13].
Control for confounding variables is crucial in analysis of
outcomes studies, as factors such as the patient demo-
graphics, the severity of underlying illness, and the comorbid
conditions may be closely associated with both the exposure
(e.g. resistance, infection) and the outcome studied (e.g.
death, length of stay, cost). Failure to adjust for such
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confounders will bias the results and may lead to erroneous
conclusions. Adjustment for these confounders may be
accomplished using validated tools such as the Acute
Physiology and Chronic Health Evaluation (APACHE) score
when studying the effect of intensive care unit events (such
as acquisition of a resistant pathogen) on outcomes (such as
mortality) [14].
Treating a confounder as an intermediate variable, or
conversely, treating an intermediate variable as a confounder,
may lead to false results. How, then, do we differentiate
between the two? Both intermediate variables and con-
founders are associated with the outcome. The intermediate
variable, however, unlike the confounder, is caused by the
exposure. In the case of resistant hospital-acquired
pneumonia, it is plausible that the natural course of the
disease would entail pneumonia followed by bacteremia,
leading to sepsis, septic shock, and consequent death.
Nonintermediate variables such as the Charlson score, by
contrast, predate the infection and are therefore not in the
temporal pathway between infection and death.
A more subtle problem arises when an intermediate variable
is itself a confounder. An example of this potential pitfall
occurs when adjusting for physiological scores measured at
the time of the onset of the infection. Recording the APACHE
score at the onset of infection is problematic since the patient
may already demonstrate signs of infection. In such a case,
the APACHE score itself, utilized by the investigator to adjust
for confounding, becomes an intermediate variable. The
APACHE score should ideally be recorded before any signs
of infection appear, but such data are often not available.
In constructing multivariable models in outcomes studies, the
investigators must identify which of the included covariates
are intermediate variables. These variables must be
accounted for in the analysis in a way that accounts for their
being intermediate [12,15]. Our suggestion for a way to
manage such analyses is to run the model with and without
each intermediate variable, individually and together, in order
to determine as accurately as possible the true independent
predictors of the outcome under study.
Zavascki and colleagues, in the first reported outcomes study
of MBL production in patients with hospital-acquired pneu-
monia, have appropriately accounted for the intermediate
variable of inappropriate therapy, and thereby provided a
plausible explanation for the effect of resistance on mortality
via its effect on appropriateness of therapy [8]. We stand to
gain even more insight into the effect of resistance on
mortality if further analyses of these data take appropriate
account of the additional intermediate variables of
sepsis/septic shock and bacteremia. As multidrug resistance
is an emerging threat among critically ill patients, future
studies will be required to quantitate its effect in infections
within this patient population. Analyses that deal
appropriately with intermediate variables, including sepsis,
shock, and physiological scores at time of infection, stand to
provide the most valid information.
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